{"id":8103,"date":"2011-05-02T16:29:56","date_gmt":"2011-05-02T20:29:56","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?p=8103"},"modified":"2011-07-19T17:44:26","modified_gmt":"2011-07-19T21:44:26","slug":"fda-approves-new-drug-for-type-2-diabetes","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2011\/05\/02\/fda-approves-new-drug-for-type-2-diabetes\/","title":{"rendered":"FDA Approves New Drug for Type 2 Diabetes"},"content":{"rendered":"<p><a href=\"http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm253501.htm\">The  FDA announced today<\/a> that it has approved linagliptin, a new drug  for type 2 diabetes. The DPP-4 inhibitor was developed by Eli Lilly and  Boehringer Ingelheim and will be sold under the brand name of Tradjenta.<\/p>\n<p>Linagliptin  was studied in 3,800 patients with type 2 diabetes, the FDA said, and  was better than placebo in controlling glucose. The drug has been  studied as monotherapy and in combination with other drugs indicated for type 2 diabetes,  but its use with insulin has not been tested and it should not be used  in people with type 1 diabetes.<\/p>\n<p>According to the FDA, the most  common side effects of the drug are upper respiratory infection, stuffy  or runny nose, sore throat, muscle pain, and headache.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The FDA announced today that it has approved linagliptin, a new drug for type 2 diabetes. The DPP-4 inhibitor was developed by Eli Lilly and Boehringer Ingelheim and will be sold under the brand name of Tradjenta. Linagliptin was studied in 3,800 patients with type 2 diabetes, the FDA said, and was better than placebo [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,7],"tags":[826,825,469],"class_list":["post-8103","post","type-post","status-publish","format-standard","hentry","category-general","category-prevention","tag-dpp-4-inhibitors","tag-linagliptin","tag-type-2-diabetes"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/8103","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=8103"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/8103\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=8103"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=8103"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=8103"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}